Rock Springs Capital Management LP Neurocrine Biosciences Inc Transaction History

Rock Springs Capital Management LP

$2.51 Billion
Q4 2024

A detailed history of Rock Springs Capital Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rock Springs Capital Management LP holds 720,500 shares of NBIX stock, worth $82 Million. This represents 3.93% of its overall portfolio holdings.

Number of Shares

720,500

Previous 939,000 23.27%

Holding current value

$82 Million

Previous $108 Million 9.03%

% of portfolio

3.93%

Previous 3.68%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $24.4 Million - $30.5 Million	-218,500 Reduced 23.27%	720,500 $98.3 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $114,580 - $153,150	-1,000 Reduced 0.11%	939,000 $108 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $15 Million - $16.5 Million	-114,900 Reduced 10.89%	940,000 $129 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $18.4 Million - $20.3 Million	-141,100 Reduced 11.8%	1,054,900 $145 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $4.24 Million - $5.31 Million	-40,000 Reduced 3.24%	1,196,000 $158 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $4.09 Million - $5.09 Million	-43,500 Reduced 3.4%	1,236,000 $139 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $6.21 Million - $7.28 Million	69,400 Added 5.74%	1,279,500 $121 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $8.24 Million - $10.8 Million	87,600 Added 7.8%	1,210,100 $122 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.33 Million - $1.75 Million	17,500 Added 1.58%	1,122,500 $109 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $4.26 Million - $5.68 Million	53,500 Added 5.09%	1,105,000 $94.1 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $3.15 Million - $3.61 Million	36,500 Added 3.6%	1,051,500 $101 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $49 Million - $66.9 Million	-560,000 Reduced 35.56%	1,015,000 $98.7 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $9.52 Million - $11.9 Million	109,500 Added 7.47%	1,575,000 $151 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $9.52 Million - $13.4 Million	99,000 Added 7.24%	1,465,500 $141 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $1.45 Million - $2.22 Million	17,000 Added 1.26%	1,366,500 $167 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $5.37 Million - $8.13 Million	71,500 Added 5.59%	1,349,500 $117 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $3.95 Million - $5.39 Million	45,500 Added 3.69%	1,278,000 $137 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $17.6 Million - $21.3 Million	209,500 Added 20.48%	1,232,500 $111 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $12.9 Million - $16.3 Million	178,500 Added 21.14%	1,023,000 $86.4 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $3.87 Million - $5.12 Million	55,900 Added 7.09%	844,500 $74.4 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $9.81 Million - $17.9 Million	143,600 Added 22.26%	788,600 $56.3 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $1.44 Million - $1.84 Million	14,600 Added 2.32%	645,000 $79.3 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $1.82 Million - $2.56 Million	24,200 Added 3.99%	630,400 $61.9 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $9.12 Million - $11.1 Million	120,200 Added 24.73%	606,200 $50.3 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $2.69 Million - $3.57 Million	46,000 Added 10.45%	486,000 $37.7 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $21.1 Million - $27 Million	440,000	440,000 $27 Million

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Neurocrine Biosciences Inc Transaction History